TP53 and non-small cell lung carcinoma: Cancer cells with TP53 mutations have also been shown to be sensitive to the Aurora A kinase inhibitor alisertib, which is a currently in a phase II clinical study for the treatment of non-small-cell lung carcinoma (NSCLC) [68].